Novel therapeutic options for cachexia and sarcopenia

References

• Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) ‘cachexia-anorexia in chronic wasting diseases’ and ‘nutrition in geriatrics’. Clin Nutr. 2010;29(2):154–159.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495.
   PubMed Web of Science ®Google Scholar
• Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15:630–634.
   PubMed Web of Science ®Google Scholar
• Alchin DR. Sarcopenia: describing rather than defining a condition. J Cachexia Sarcopenia Muscle. 2014;5:265–268.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Lucia S, Molfino A, et al. Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia? Intern Emerg Med. 2013;8(7):553–560.
   PubMed Web of Science ®Google Scholar
• Drescher C, Konishi M, Ebner N, et al. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle. 2015;6:303–311.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Molfino A, Lucia S, et al. Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. Crit Rev Oncol Hemat. 2015;94:251–259.
   PubMed Web of Science ®Google Scholar
• Balstad TR, Kaasa S, Solheim TS. Multimodal nutrition/anabolic therapy for wasting conditions. Curr Opin Clin Nutr Metab Care. 2014;17:226–235.
   PubMed Web of Science ®Google Scholar
• Molfino A, Formiconi A, Rossi Fanelli F, et al. Cancer cachexia: towards integrated therapeutic interventions. Expert Opin Biol Ther. 2014;14(10):1379–1381.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. Int J Cardiol. 2015;184:736–742.
   PubMed Web of Science ®Google Scholar
• Molfino A, Amabile MI, Monti M, et al. Carnitine for the treatment of cachexia: lights and shadows. Int J Cardiol. 2015;198:180–181.
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother. 2012;13:2453–2472.
   PubMed Web of Science ®Google Scholar
• Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5:329–337.
   PubMed Web of Science ®Google Scholar
• Molfino A, Gioia G, Muscaritoli M. The hunger hormone ghrelin in cachexia. Expert Opin Biol Ther. 2013;13(4):465–468.
   PubMed Web of Science ®Google Scholar
• Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108–116.
   PubMed Web of Science ®Google Scholar
• Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–531. doi:10.1016/S1470-2045(15)00558-6.
   PubMed Web of Science ®Google Scholar
• Heppner KM, Tong J. Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol. 2014;171(1):R21–32.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M. Targeting cancer cachexia: we’re on the way. Lancet Oncol. 2016;17:414–415. pii: S1470-2045(16)00085-1. doi:10.1016/S1470-2045(16)00085-1.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–1547.
   PubMed Web of Science ®Google Scholar
• Molfino A, Formiconi A, Rossi Fanelli F, et al. Ghrelin: from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care. 2014;17(5):471–476.
   PubMed Web of Science ®Google Scholar
• Koshinaka K, Toshinai K, Mohammad A, et al. Therapeutic potential of ghrelin treatment for unloading-induced muscle atrophy in mice. Biochem Biophys Res Commun. 2011;412:296–301.
   PubMed Web of Science ®Google Scholar
• Llovera M, Carbó N, López-Soriano J, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 1998;133(1):83–87.
   PubMed Web of Science ®Google Scholar
• Dutta V, Guptaa S, Daburb R, et al. Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action. Pharmacol Res. 2015;99:86–100.
   PubMed Web of Science ®Google Scholar
• Subramaniam K, Fallon K, Ruut T, et al. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn’s disease. Aliment Pharmacol Ther. 2015;41(5):419–428.
   PubMed Web of Science ®Google Scholar
• McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell. 2004;119:907–910.
   PubMed Web of Science ®Google Scholar
• Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2015. pii: S1084-9521(15)00246-3. doi:10.1016/j.semcdb.2015.10.039.
   PubMed Web of Science ®Google Scholar
• Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125–139.
   PubMed Web of Science ®Google Scholar
• Ando K, Takahashi F, Kato M, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin 6-expressing lung cancer. PLoS One. 2014;9:e102436. doi:10.1371/journal.pone.0102436.
   PubMed Web of Science ®Google Scholar
• Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting IL-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656e666.
   Google Scholar
• Elkina Y, von Haehling S, Anker SD, et al. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011;2:143–151.
   PubMed Web of Science ®Google Scholar
• Lach-Trifilieff E, Minetti GC, Sheppard KA, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34(4):606–618.
   PubMed Web of Science ®Google Scholar
• Han HQ, Zhou X, Mitch WE, et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333–2347.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531–543.
   PubMed Web of Science ®Google Scholar
• Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83:2239–2246.
   PubMed Web of Science ®Google Scholar
• Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3(12):948–957.
   PubMed Web of Science ®Google Scholar
• Ebner N, Springer J, Kalantar-Zadeh K, et al. Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas. 2013;75:199–206.
   PubMed Web of Science ®Google Scholar
• Dubois V, Laurent M, Boonen S, et al. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci. 2012;69(10):1651–1667.
   PubMed Web of Science ®Google Scholar
• Dubois V, Simitsidellis I, Laurent MR, et al. Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage. Endocrinology. 2015;156:4522–4533.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14:335–345.
   PubMed Web of Science ®Google Scholar
• Srinath R, Dobs A. Enobosarm (GTx-024, S-22): a potential treatment for cachexia. Future Oncol. 2014;10:187–194.
   PubMed Web of Science ®Google Scholar
• Fearon K, Argiles JM, Baracos VE, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle. 2015;6:272–274.
   PubMed Web of Science ®Google Scholar
• Chen L, Nelson DR, Zhao Y, et al. Relationship between muscle mass and muscle strength, and the impact of comorbidities: a population-based, cross-sectional study of older adults in the United States. BMC Geriatr. 2013;13:74.
   PubMed Web of Science ®Google Scholar
• Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr. 2014;33:737–748.
   PubMed Web of Science ®Google Scholar
• Michel JP, Cruz-Jentoft AJ, Cederholm T. Frailty, exercise and nutrition. Clin Geriatr Med. 2015;31:375–387.
   PubMed Web of Science ®Google Scholar
• Kirby TJ, Chaillou T, McCarthy JJ. The role of microRNAs in skeletal muscle health and disease. Front Biosci (Landmark Ed). 2015;20:37–77.
   PubMed Web of Science ®Google Scholar
• Siddeek B, Inoubli L, Lakhdari N, et al. MicroRNAs as potential biomarkers in diseases and toxicology. Mutat Res Genet Toxicol Environ Mutagen. 2014;764-765:46–57.
   PubMed Web of Science ®Google Scholar
• He WA, Calore F, Londhe P, et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014;111(12):4525–4529.
   PubMed Web of Science ®Google Scholar